Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
IPO Year: 2018
Exchange: NASDAQ
Website: enterabio.com
3 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024. "The third quarter of 2024 drew consistent attention to our pivotal-staged clinical asset, EB613, the first oral PTH(1-34) tablet treatment dedicated to post-menopausal women with high risk osteoporosis. Entera's proprietary N-Tab™ platform consistently delivered across our oral GLP-2 tablet, oral GLP-1/Glucagon tablet and confidential hypoparathyroidism tablet program. Finally, we are humbled by key additions
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ:OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera's proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonist GLP-1/glucagon peptide as a potential once-daily treatment for patients with obesity, metabolic and fibrotic disorders. OXM is a naturally occurring peptide hormone found in the small intestine that
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor and scientific conferences: H.C. Wainwright 26th Annual Global Investment Conference (Presentation and 1x1) Date and Time: September 9, 2024 at 7am ETLocation: Virtual, September 9-11, 2024 American Society for Bone and Mineral Research 2024 Annual Meeting (Poster and 1x1) Date and Time: Saturday, September 28, 2024, 2:15 – 3:45PM Location: In person, September 26-29, 2024 Toronto, Canada 7th Annual Evercore ISI Heal
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024. "We continue to deliver strong execution with key milestones achieved during the second quarter of 2024 across each of our N-Tab™ oral peptide programs dedicated to patients with OBGYN/endocrinology, GI and metabolic diseases," said Miranda Toledano, Entera's CEO. "Importantly, we are now just five months away from FDA's potential landmark ruling on the ASBMR-FNIH SABRE regulatory endpoint for osteoporosi
JERUSALEM, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that new comparative pharmacological data for its investigational agent EB613 vs. Forteo® was selected for presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting which will be held on September 27-30, 2024 in Toronto, ON, Canada. EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) mini tablet therapy for post-menopausal women with high risk osteoporosis. It is estimated that 50 percent of women and 20 percent of me
JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced Phase 1 clinical data for its hypoparathyroidism focused investigational program, EB612, as presented on June 1st at the Endocrine Society ENDO 2024 Annual Meeting. Entera's EB612 program aims to provide the first oral PTH daily tablet hormone replacement therapy for patients suffering from hypoparathyroidism. Late stage investigational PTH replacement treatments include TransCon PTH (palopegteriparatide) by Ascendis Pharma A/S and eneboparatide (AZP-3601) by Amolyt Pharma. Both thes
JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle mana
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it has been selected to present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting which will be held on June 1-4, 2024 in Boston, Massachusetts. The EB612 program is being developed by Entera to provide the first oral PTH(1-34) tablet peptide replacement therapy for patients suffering from hypoparathyroidism. Hypoparathyroidism is characterized by deficient PTH production, hypocalcemia and hyperphosphatemia. Standard treatments include s
JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024. "Entera is off to a strong start in 2024 thanks to the growth strategy we implemented in 2023, expanding our N-Tab™ therapeutic pipeline with potential first in class oral GLP-2, GLP-1/glucagon and PTH(1-34) peptide treatments for patients with GYN/endocrine, metabolic and gastrointestinal disorders. We thank our shareholders for their support. We are continuing on our mission to build Entera into a
JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR). Miranda Toledano, CEO of Entera, commented, "We are excited to share that data from our successful Phase 2 study of EB613 has been accepted and now published in the prestigious JBMR. We believe EB613 addresses the current treatment gap in osteoporosis as the
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price target.
Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced Phase 1 clinical data for its hypoparathyroidism focused investigational program, EB612, as presented on June 1st at the Endocrine Society ENDO 2024 Annual Meeting.Entera's EB612 program aims to provide the first oral PTH daily tablet hormone replacement therapy for patients suffering from hypoparathyroidism. Late stage investigational PTH replacement treatments include TransCon PTH (palopegteriparatide) by Ascendis Pharma A/S and eneboparatide (AZP-3601) by Amolyt Pharma. Both these modalities require patients to administer injec
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price target.
Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year.
Entera Bio (NASDAQ:ENTX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.06) by 183.33 percent. This is a 162.5 percent increase over losses of $(0.08) per share from the same period last year.
Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR). Miranda Toledano, CEO of Entera, commented, "We are excited to share that data from our successful Phase 2 study of EB613 has been accepted and now published in the prestigious JBMR. We believe EB613 addresses the current treatment gap in osteoporosis as the first oral, osteoanabolic (bone building) once-daily t
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price target.
Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of orally delivered peptides, announced today that The American Society for Bone and Mineral Research (ASBMR) announced on March 25 2024 that the U.S. Food and Drug Administration (FDA) has communicated to the SABRE (Study to Advance BMD as a Regulatory Endpoint) project team that a ruling to qualify the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs would be provided within 10 months. The proposed registrational Phase 3 study for EB613, Entera's lead clinical candidate, which is a first-in-class PTH(1-34) dail
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates. Corporate Updates: Achieved FDA Agreement for Pivotal Study of EB613, the World's First Daily Bone Forming Oral PTH Tablet On October 6th, 2022, Entera announced that it had successfully completed its Type C meeting and reached a record agreement with the U.S. Food and Drug Administration (FDA) that a single pivotal Phase 3 placebo-controlled study could support a New Drug Application (NDA)
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and operating results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Highlights EB613 Clinical Update: Entera's lead clinical candidate, EB613, an oral formulation of human parathyroid hormone (1-34), o
BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the three months ended March 31, 2022 on Thursday, May 12, 2022 at 8:30 AM EDT. Thursday, May 12, 2022, 8:30 AM EDTDomestic: 877-269-7756International: 201-689-7817Israel: 1809406247Conference ID: 13728252 Webcast: Entera Bio Earnings Webcast A replay of the webcast will be archived on Entera's website for approximately 45 days following the call. About Entera BioEntera is a leader in the development of orally delivered large molecule therapeutics for use in a
— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral delivery technology platform advances with more indications, inventions, patents, and collaborations —— Company to host conference call and webcast today at 8:30 AM EST — BOSTON and JERUSALEM, March 08, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced financial and operating results for the year ended December 31, 2021, and provided an update on its clinical and pre-clinical programs. 2021 and Recent Highlights Successful End of Phase 2 Meet
BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the 12 months ended December 31, 2021 on Tuesday, March 8, 2022 at 6:30 AM EST. Entera's management will host a conference call later that morning, Tuesday, March 8, at 8:30 AM EST to discuss the results for the year. A question-and-answer session will follow Entera's remarks. To participate in the live call, please dial (877) 269-7756 (US) or (201) 689-7817 (international) or 1809406247 (Israel) and provide the conference ID "13727633" five to ten minutes befor
‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒ ‒ Preparing for End of Phase 2 Meeting with FDA for Planned Pivotal One-year Phase 3 Study Comparing Changes in Lumbar Spine BMD in Patients Treated with EB613 Versus Treatment with Forteo®, as per a 505(b)(2) Pathway ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. ET ‒ BOSTON and JERUSALEM, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced financial and operating results for the quarter ended June 30, 2021.
BOSTON and JERUSALEM, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2021, on August 16, 2021, at 06:30am ET. Entera's management will host a conference call on Monday, August 16, 2021, at 8:30 a.m. EDT to discuss the results for the quarter. A question-and-answer session will follow Entera's remarks. To participate on the live call, please dial (855) 547-3865 (US) or (409) 217-8787 (international) or 1809457877 (Israel) and provide the conference ID "2056337" five to ten minutes before the start of the call
10-Q - Entera Bio Ltd. (0001638097) (Filer)
8-K - Entera Bio Ltd. (0001638097) (Filer)
S-8 - Entera Bio Ltd. (0001638097) (Filer)
10-Q - Entera Bio Ltd. (0001638097) (Filer)
8-K - Entera Bio Ltd. (0001638097) (Filer)
8-K - Entera Bio Ltd. (0001638097) (Filer)
DEFA14A - Entera Bio Ltd. (0001638097) (Filer)
ARS - Entera Bio Ltd. (0001638097) (Filer)
DEF 14A - Entera Bio Ltd. (0001638097) (Filer)
PRE 14A - Entera Bio Ltd. (0001638097) (Filer)
B. Riley Securities initiated coverage of Entera Bio with a rating of Buy and set a new price target of $9.00
Aegis Capital initiated coverage of Entera Bio with a rating of Buy and set a new price target of $12.00
Maxim Group reiterated coverage of Entera Bio with a rating of Buy and set a new price target of $10.00 from $5.00 previously
4 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
4 - Entera Bio Ltd. (0001638097) (Issuer)
JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle mana
JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has appointed Haya Taitel, Head of Sanofi's Global Transplant Franchise as an independent director to the Company's Board of Directors. "We are thrilled that Haya has joined our Board," said Miranda Toledano, Chief Executive Officer of Entera. "With more than 30 years of experience building industry-leading commercial organizations across big pharma and biotech, Haya brings a veteran and unique perspective to Entera's Board of Directors. We believe that Haya's track record shepherd
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administration (FDA) has granted Entera's request for a Type C Meeting based on the revised phase 3 registrational study for lead clinical asset, EB613 (oral formulation of PTH (1-34, teriparatide), as the first oral anabolic drug to treat post-menopausal women with osteoporosis. The meeting is expected in H2 2022Following its End of Phase 2 Meeting with the FDA, Entera designed the pivotal study for EB613 as an 18 month double blind placebo-contro
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera's existing board members, as Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy, effective immediately. "Miranda is an accomplished leader in the biotechnology industry with almost 25 years of C-level leadership, principal investment and capital markets experience," commented Spiros Jamas, Chief Executive Officer of Entera Bio. "Ms. Toledano, as a member of our Board of Directors since 2018, has an extensive understanding of Entera's
BOSTON and JERUSALEM, Israel, April 15, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of veteran finance and operations executive Ramesh Ratan as U.S. Chief Financial Officer. Mr. Ratan replaces Jonathan Lieber who was serving as Entera's interim U.S. CFO. Mr. Ratan brings 40 years of experience at biomedical, tech, and Fortune 500 companies in senior, executive, vice president, and C-level positions. He was most recently CFO, Head of Manufacturing, and Corporate Secretary at AOBiome. He served as CFO at Xcellerex, Enanta Pharmaceuticals, Repligen, and held positions at
BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a member of its Board of Directors. Dear Shareholders, We hope you and your family have fared well and been healthy during a difficult 2020. As we begin the new year, we are hopeful the global community, with a little help from the biopharmaceutical industry, will overcome the most significant pandemic in a century. Personally, I am thrilled to start 2021 leading Entera and its highly promising oral protein drug deli
SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)
SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)
SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)
SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)
SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)
SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)
SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)
SC 13G - Entera Bio Ltd. (0001638097) (Subject)
SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)
SC 13G - Entera Bio Ltd. (0001638097) (Subject)